Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR

Relay Therapeutics, Inc.

2023-Q2 EPS reported -$1.59 revenue$345,000

Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.
Cash and investments $871.6M as of June 30, 2023; expected to fund operations into H2 2025.
Initiated RLY-2608 600mg BID + fulvestrant dose expansion; interim CBR 86% (6/7 evaluable pts) with 1 partial response.
No Grade 3+ hyperglycemia/diarrhea or AE-related discontinuations across 43 breast cancer patients; next data update in 2024.
Anticipated milestones: RLY-4008 pivotal cohort enrollment H2 2023, ERα degrader candidate nomination 2023, RLY-2139 start early 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Relay Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $98.5 million, EPS net loss per share of $0.81.

Period: second quarter 2023
Net income: Net loss was $98.5 million
EPS: net loss per share of $0.81
Result: reported results

Exact text from the filing

Net loss was $98.5 million for the second quarter of 2023, or a net loss per share of $0.81

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.